Complete this CE activity online at ProCE.com/InsulinPart2
|
|
- Leo Bradford
- 5 years ago
- Views:
Transcription
1 Complete this CE activity online at ProCE.com/InsulinPart2
2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over 2 years. He was diagnosed with T2DM 6 years ago. He has tried both metformin and sulfonylureas but has since discontinued them because of intolerable GI side effects and efficacy concerns, respectively. Three months ago, he had an A1C of 8.4%, with no changes to his diabetes therapy at that time. He presents today for a follow up visit. Medical History T2DM x 6 years HTN x 5 years Dyslipidemia for 2 years Social History Retired bank manager Active health insurance Nonsmoking with no illicit drug use Infrequent caffeine use (<1 times per week) Occasional alcohol use (~1 drink per week) Self reported largest meal of the day is dinner with evening snacks Family History Diabetes Mellitus Type 2 (mother) Myocardial Infarction (father) Current Medications Insulin glargine (pen) 80 units twice per day Insulin aspart (pen) units per meal + Correction Lisinopril 10 mg daily Atorvastatin 10mg daily Physical Examination Height 5 feet 6 inches Weight 280 lbs Body Mass Index (BMI) 45 kg/m 2 Blood Pressure 124/76 mm Hg Heart rate 74 bpm Slightly decreased sensation in both feet bilaterally; no evidence of retinopathy Laboratory Results (Sample obtained this morning) A1C 8.7% Serum Creatinine (SCr) 1.2 mg/dl Urinary albumin:creatine ratio (ACR) <10 mg/g creatinine Estimated glomerular filtration ratio (egfr) >100 ml/min/1.73 m 2 Low density lipoprotein cholesterol (LDL C) 105 mg/dl High density lipoprotein cholesterol (HDL C) 50 mg/dl Triglycerides 140 mg/dl
3 Question 1 What would you do first? A. Ask John how he injects his insulin B. Ask John how many times a day he tests his blood sugar C. Have John show you how he injects his insulin D. Have John tell you what he eats in a typical day Question 2 Once you are confident that John s injection technique is appropriate, what medication change would you make? A. Increase insulin glargine U 100 to 60 units TID B. Increase insulin aspart to 65 units TID C. Switch to regular insulin U 500 D. Switch to insulin glargine U 300 E. No change is needed at this time Question 3 John s prescriber agrees that concentrated insulin would be appropriate and would like to switch him to U 500. For a total daily dose of 300 units to be given twice daily, how would you instruct John to draw up 150 units of U 500 insulin? A. Using a U 100 syringe, draw to the 60 units marking B. Using a U 100 syringe, draw to the 30 units marking C. Using a tuberculin syringe, draw 0.2 ml D. Using a tuberculin syringe, draw 0.4 ml
4 Case 2: A 60 year old female with T2DM History and Presentation Elaine is 60 years old, and is a new patient at your pharmacy/clinic. She was diagnosed with T2DM 5 years ago. She lives with her family, her husband and their son (age 24) and daughter (age 20). You have no previous laboratory information for Elaine but when you asked about her A1C, she stated that it was high the last time. Medical History HTN x 6 years Dyslipidemia for 6 years T2DM x 5 years Social History Works as a crossing guard for the local elementary school Active health insurance Nonsmoking with no illicit drug use No caffeine use Occasional alcohol use (~4 drinks per week) Self reported large breakfast and dinner; smaller meal, or no meal, around lunchtime Family History Diabetes Mellitus Type 2 (mother) Current Medications Insulin glargine (vial) 80 units once daily at bedtime Insulin Lispro (vial) 25 units per meal + correction with snacks Lisinopril 20 mg once daily Simvastatin 40 mg once daily Aspirin 81 mg once daily Physical Examination Height 5 feet 0 inches Weight 160 lbs Body Mass Index (BMI) 31 kg/ m 2 Blood Pressure 118/78 mm Hg Heart rate 90 bpm No evidence of retinopathy or neuropathy Laboratory Results (Sample obtained this morning) A1C 9% Serum Creatinine (SCr) 0.6 mg/dl Urinary albumin:creatine ratio (ACR) <10 mg/g creatinine Estimated glomerular filtration ratio (egfr) >100 ml/min/1.73 m 2 Low density lipoprotein cholesterol (LDL C) 95 mg/dl High density lipoprotein cholesterol (HDL C) 35 mg/dl Triglycerides 185 mg/dl
5 Question 1 After a comprehensive review, you are confident with Elaine s injection technique and adherence to her current medications. How would you optimize her diabetes management? A. Increase insulin lispro 40 units TID B. Switch to insulin regular U 500 BID C. Switch to insulin regular U 500 TID D. Switch insulin glargine to insulin detemir 40 units BID E. Switch to insulin glargine U 300 only Question 2 Based on the information provided, which of the following is the best rationale that makes Elaine a good candidate for U 500? A. She has a good support system and no physical impairments B. She has a stable meal plan/schedule C. She is already on a bolus insulin regimen D. She is on a high dose of basal insulin regimen Question 3 The endocrinologist would like to try switching Elaine to concentrated insulin, specifically U 500. What is the total daily dose, and how would you instruct her to draw up the U 500 insulin? A. 155 units total daily dose; using a U 100 syringe, draw to the 50 units marking B. 105 units total daily dose; using a U 100 syringe, draw to the 30 units marking C. 105 units total daily dose; using a tuberculin syringe, draw 0.2 ml D. 155 units total daily dose; using a tuberculin syringe, draw 0.1 ml
6 Case 3: 60 year old female with T2DM History and Presentation Margaret is a 60 year old new patient at your clinic. She was diagnosed with T2DM 5 years ago. She is a widow who lives alone with no children. You have no previous laboratory information for Margaret but when you asked about her A1C, she stated that it was high the last time. Additionally, she says that she experiences muscle cramping in her legs, usually around lunchtime and dinnertime. Medical History HTN x 6 years Dyslipidemia x 6 years T2DM x 5 years Arthritis x 1 year Glaucoma x 6 months Social History Works as a crossing guard for the local elementary school Active health insurance Caffeine use = 2 cups coffee daily Occasional alcohol use (~4 drinks per week) Self reported large breakfast and dinner; smaller meal, or no meal, around lunchtime Family History Diabetes Mellitus Type 2 (mother) Current Medications Insulin glargine (pen) 80 units once daily at bedtime Insulin Lispro (pen) 25 units per meal + correction with snacks Lisinopril 20 mg once daily Simvastatin 40 mg once daily Aspirin 81 mg once daily Naproxen (OTC) 275mg twice daily (with food) Latanoprost 0.005% 1 drop in each eye daily Physical Examination Height 5 feet 0 inches Weight 160 lbs Body Mass Index (BMI) 31 kg/m 2 Blood Pressure 120/76 mm Hg Heart rate 70 bpm Increased intraocular pressure and mild retinopathy Laboratory Results (Sample obtained this morning) A1C 9% Serum Creatinine (SCr) 0.6 mg/dl Urinary albumin:creatine ratio (ACR) <10 mg/g creatinine Estimated glomerular filtration ratio (egfr) >100 ml/min/1.73 m 2 Low density lipoprotein cholesterol (LDL C) 95 mg/dl High density lipoprotein cholesterol (HDL C) 35 mg/dl Triglycerides 185 mg/dl
7 Question 1 After a comprehensive review, you are confident with Margaret s injection technique and adherence to her current medications. How would you optimize her diabetes management? A. Increase insulin lispro to 27 units TID B. Start liraglutide once daily C. Switch to regular insulin U 500 D. Switch insulin glargine to insulin detemir 40 units BID E. Switch to insulin glargine U 300 only Question 2 Why isn t Margaret a good candidate for U 500 therapy? (Select all that apply) A. Glaucoma B. Arthritis C. Hypertension D. Dyslipidemia E. Lives alone
8 Case 4: A 56 year old female with T2DM History and Presentation Rachel is 56 years old and has been visiting your pharmacy/clinic for just over 4 years. She was diagnosed with T2DM 4 years ago. The only problem she reports is occasional episodes of nocturnal hypoglycemia (about 3 to 5 per month). She was just discharged from the hospital today due to a severe hypoglycemic event that occurred at 3 AM 2 days ago. When she was monitored 3 months ago, Rachel had an A1C of 9.6%. She presents today with a new prescription for insulin lispro (pen) 10 units TID before meals. However, she says that she does not want to start bolus insulin because she has erratic meal and work schedules. Rachel tells you to throw away the prescription for lispro, as she will never use it. Medical History T2DM x 4 years Dyslipidemia x1 year Social History High school principal Active health insurance Nonsmoking with no illicit drug use Frequent caffeine use (3 4 cups daily) Infrequent alcohol use (~1 drink per 2 weeks) Meal schedule and size is erratic because of her work Family History Cardiovascular disease (mother) Diabetes mellitus type 2 (father) Current Medications NPH (pen) 63 units twice per day; morning (7 AM) and 2 hours before bed (9 PM) Metformin 1000 mg daily Sitagliptin 100 mg daily Simvastatin 20 mg daily Physical Examination Height 5 feet 8 inches Weight 210 lbs Body Mass Index (BMI) 32 kg/m 2 Blood Pressure 136/84 mm Hg Heart rate 72 bpm No evidence of retinopathy or neuropathy Laboratory Results (Sample obtained this morning at the hospital) A1C 8.6% Serum Creatinine (SCr) 1.1 mg/dl Urinary albumin:creatine ratio (ACR) <10 mg/g creatinine Estimated glomerular filtration ratio (egfr) >100 ml/min/1.73 m 2 Low density lipoprotein cholesterol (LDL C) 110 mg/dl High density lipoprotein cholesterol (HDL C) 38 mg/dl Triglycerides 190 mg/dl
9 Question 1 After a comprehensive review, you are confident with Rachel s injection technique and adherence to her current medications. What medication change would you make? A. Start insulin lispro at 10 units TID B. Switch to regular insulin U 500 C. Switch to insulin glargine U 100 D. Switch to insulin glargine U 300 E. No change is needed at this time Question 2 Rachel s prescriber agrees to switch to U 300 insulin glargine. What would be your recommendation for switching from 63 units twice daily (126 units/day) NPH to insulin glargine U 300? A. Using a U 100 syringe, draw to 21 units marking (63 units) and inject twice daily B. Using a U 100 syringe, draw to 49 units marking (126 units) and inject once daily C. Using the U 300 pen, dial to 126 units and inject once daily D. Using the U 300 pen, dial to 51 units and inject twice daily Question 3 Rachel s prescriber asks you how insulin glargine can be titrated? You respond: A. Rachel should return to the prescriber's office in 2 days and the prescriber can advise how to titrate. B. Rachel should return to the pharmacy/clinic in 2 days and the pharmacist can advise how to titrate. C. Rachel can titrate the dose herself every 4 days, based on a protocol provided by her prescriber. D. Rachel should wait 3 months for the next A1c level and then have the prescriber titrate the dose.
10 Case 5: A 59 year old male with T2DM History and Presentation Ray is 59 years old and has been visiting your pharmacy/clinic for just over 1 year. He was diagnosed with T2DM 4 years ago. The only problem he reports is frequent drowsiness. He does not want to start bolus insulin because he "already takes 1 shot per day and that's enough." Three months ago, he had an A1C of 8.6%, and presents today for a follow up visit. Medical History T2DM x 4 years Dyslipidemia x 1 year Social History Office Depot store manager Active health insurance Nonsmoking with no illicit drug use Frequent caffeine use (3 4 cups daily) Alcohol use (~1 drink per day, maybe 2 on Sunday) Meal schedule and size is erratic because of his work Family History Cardiovascular disease (mother) Diabetes mellitus type 2 (father) Current Medications Insulin glargine U 100 (pen) 52 units 1 hour before bed (11:30 PM) Increased from 46 units 6 months ago Increased from 40 units 9 months ago Increased from 34 units 12 months ago Metformin 1000 mg daily Sitagliptin 100 mg daily Simvastatin 20 mg daily Physical Examination Height 5 feet 8 inches Weight 210 lbs Body Mass Index (BMI) 32 kg/m 2 Blood Pressure 136/84 mm Hg Heart rate 72 bpm No evidence of retinopathy or neuropathy Laboratory Results (Sample obtained this morning) A1C 9.1% Serum Creatinine (SCr) 1.1 mg/dl Urinary albumin:creatine ratio (ACR) < 10 mg/g creatinine Estimated glomerular filtration ratio (egfr) > 100 ml/min/1.73 m 2 Low density lipoprotein cholesterol (LDL C) 110 mg/dl High density lipoprotein cholesterol (HDL C) 38 mg/dl Triglycerides 190 mg/dl
11 Question 1 What would you do first? A. Ask Ray how he injects his insulin. B. Ask Ray how many times a day he tests his blood sugar. C. Have Ray show you how he injects his insulin. D. Have Ray tell you what he eats in a typical day. Question 2 After observing Ray s injection method, you notice inaccurate technique. Which of the following is NOT part of appropriate injection technique? A. Patient attaches the needle and removes both the outer (large) cap and the inner (smaller) protective cap. B. Patient dials a 2 unit dose, holds the pen upright, depresses the button, and releases a 2 unit air shot as a priming method. C. Patient dials his dose of 52 units, injects the needle into his skin at a 90 degree angle, then dials the knob back down to "zero" on the window. D. Patient injects the needle into the skin and holds in place for 8 seconds before removing the needle from his abdomen. Question 3 After carefully reviewing the appropriate injection technique with Ray and watching him demonstrate it back correctly, how soon should you schedule him for follow up? A. 3 to 7 days B. 2 to 3 weeks C. 1 month D. 3 months
12 Case 6: A 49 year old male with T2DM History and Presentation Steve is 49 years old and has been visiting your pharmacy/clinic for over 2 years. He was diagnosed with T2DM 6 years ago. Three months ago, he had an A1C of 9.2%, with no changes to his diabetes therapy at that time. He presents today for a follow up visit. Medical History T2DM x 6 years Dyslipidemia x 2 years Social History Community church custodian Active health insurance Nonsmoking with no illicit drug use Caffeine use (1 2 cups daily) Occasional alcohol use (~1 3 drinks per week) Self reported largest meals of the day are breakfast and dinner. He does not eat lunch or snacks. Family History Diabetes Mellitus Type 2 (mother) Current Medications Metformin 1000 mg twice daily Linagliptin 5 mg daily Atorvastatin 10 mg daily Physical Examination Height 5 feet 6 inches Weight 280 lbs Body Mass Index (BMI) 45 kg/m 2 Blood Pressure 124/76 mm Hg Heart rate 74 bpm Mild retinopathy reported; no neuropathy Laboratory Results (Sample obtained this morning) A1C 9.7% Serum Creatinine (SCr) 1.0 mg/dl Urinary albumin:creatine ratio (ACR) <10 mg/g creatinine Estimated glomerular filtration ratio (egfr) >100 ml/min/1.73 m 2 Low density lipoprotein cholesterol (LDL C) 105 mg/dl High density lipoprotein cholesterol (HDL C) 50 mg/dl Triglycerides 140 mg/dl
13 Question 1 Steve s physician wants to start him on insulin. Steve is agreeable, but does not want to inject himself more than once daily. He is also worried about hypoglycemia, as he lives alone and has minimal family in the area to call on for help. What insulin regimen would you recommend? A. Insulin determir U 100 at bedtime B. Insulin glargine U 100 at bedtime C. Insulin glargine U 300 at bedtime D. NPH insulin at bedtime E. NPH insulin before breakfast Question 2 Steve s physician agrees with your recommendation of insulin glargine U 300, and Steve is agreeable to this therapy. What dose would you start him on? A. 10 units daily B. 25 units daily C. 50 units daily D. 56 units daily Complete this CE activity online at ProCE.com/InsulinPart2
CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia
CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationCase Studies in T2DM A Comprehensive Management Approach
Case Studies in T2DM A Comprehensive Management Approach John E. Anderson, MD The Frist Clinic Nashville, TN 43 yo Latina woman with 5 yrs T2DM. Originally diagnosed with PCOS and IGT by GYN at 32 yo.
More informationInsulin Initiation, titration & Insulin switch in the Primary Care-KISS
Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationInsulin Cases: Inpatient and Outpatient
Insulin Cases: Inpatient and Outpatient Susan Cornell, BS, PharmD., CDE, FAPhA, FAADE Associate Director, Office of Experiential Education Associate Professor of Pharmacy Practice Midwestern University
More informationIt Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia
It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia Jacqueline LaManna, PhD, ANP BC, BC ADM, CDE Holly Divine, PharmD, BCACP, CGP, CDE, FAPhA Disclosures Dr. Jacqueline LaManna
More informationSafe use of insulin regular concentrated (500 units/ml) in severe insulin resistance
Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance Jodie S. Gee, Pharm.D., BCACP, CDE Clinical Pharmacy Specialist-Ambulatory Care Harris Health System Objectives To be
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationTo test your basal rates it will be important that you keep the same schedule on the days you are testing. Do not do basal rate testing if you:
Basal Rate Testing: Your provider has recommended that you complete one or more basal rate tests. These worksheets will help you in testing your pump settings and making small changes to make sure your
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationModule 5. Understanding Insulin Therapy
Module 5. Understanding Insulin Therapy EDUCATIONAL OBJECTIVES Upon completion of this activity, participants will be better able to: 1. Define the basic physiologic concept of basal-bolus insulin; 2.
More informationPatient is a 60 YO MALE seen in clinic for diabetes management follow-up. Allergies/ADEs: FLUNISOLIDE, PRIMIDONE, ALEVE CAPLET, CARBAMAZEPINE
Patient is a 60 YO MALE seen in clinic for diabetes management follow-up. Allergies/ADEs: FLUNISOLIDE, PRIMIDONE, ALEVE CAPLET, CARBAMAZEPINE Dx/Hx: uncontrolled DM and HTN Lifestyle: Patient usually sleeps
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationReason for referral: provide patient education on management of hypoglycemia and glucose monitor
Meet Robin Sawyer (otherwise known as PT 1): Let s Create a Care Plan! Reason for referral: provide patient education on management of hypoglycemia and glucose monitor History of present illness: 40 45
More informationVS: BP 165/90, P 98, RR 18, T 37 C; waist circ 38 in, Wt 240 lbs (109 kg), Ht 5'8''
IMC Didactic Case-Diabetes Mellitus Chief Complaint "I was recently diagnosed with diabetes and would like to have my blood sugar tested. I think that my blood sugar is running low because I have the shakes
More informationYour Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine
Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationABFM Diabetes SAM Part 4
ABFM Diabetes SAM Part 4 37. A 55-year-old male with type 2 diabetes mellitus has a chronic history of reduced libido and erectile dysfunction. On examination you note hepatomegaly and mild testicular
More informationQuestions may not always match the order of those online. Please be sure to read the questions when completing the online test.
Module 13 Part 1 Questions may not always match the order of those online. Please Case #1 Fred W. Fred W. is in to see you for a referral from his family physician. In the referral letter, the family physician
More informationHave participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call, , mail).
Blood Pressure Management and Control Protocol BP Management: A) BP goal: Achieve blood pressure values less than 130/80mmHg. B) Process: Have participants measure their blood pressure daily at a standard
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More informationImportant Stuff. Basal Bolus What Adjustments? Pt weighs 80kg
Diabetes Boot Camp Class 4 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Special Insulin and Pattern Management Diabetes Education Services 1998-2015. All rights
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More information5/16/2018. Insulin Workshop. Disclosures to Participants. Learning Objectives. This presentation will cover the following learning objectives:
Insulin Workshop Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Holly Divine, PharmD, BCACP, BCGP, CDE,
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationAll Things Insulin: Dosing, Monitoring, Titrating, Transitioning
All Things Insulin: Dosing, Monitoring, Titrating, Transitioning Target Audience: Pharmacists ACPE#: 0202-0000-18-052-L01-P Activity Type: Application-based Disclosures Stuart Haines declares that he has
More informationNo disclosures. Diabetes Test Topics. Case #1. Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan
Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan No disclosures Sarah Kim, MD Assistant Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March
More informationAdjusting Insulin Doses
Adjusting Insulin Doses Everyone with diabetes, including you, will need to adjust your insulin doses at some time. There are several reasons why a person may need an insulin adjustment. These reasons
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationSponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationApplication of the Diabetes Algorithm to Patients
Application of the Diabetes Algorithm to Patients Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationAppendix A: Sample Patient Profiles and Prescriptions
Appendix A: Sample Patient Profiles and Prescriptions (For Pharmacist Use) Sample Patient Profile 1 Name Mike Monroe Date of Birth 01/01/1957 Address 555 Happy Lane Phone 123-456-7890 Tucson, AZ 85704
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationLET S TALK INSULIN THE BASICS
LET S TALK INSULIN THE BASICS AUTHOR S DISCLOSURES Contracted for program development for Lifescan Canada Speaker for Lifescan, Lilly, BI, Consultant for Lilly, Janssen, Novo Nordisk, Lifescan Canada OBJECTIVES
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationInsulin Optimisation Workshop. Theingi Aung & Claire Rowell
Insulin Optimisation Workshop Theingi Aung & Claire Rowell Insulin initiation and titration Insulin Preparations Rapid-acting insulin analogues: onset of action of approximately 15 minutes and a duration
More informationInvestigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD
STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2
More informationinsulin and injections
insulin and injections Insulin is a hormone made by the beta cells in the pancreas. Insulin allows sugar to go from the bloodstream into the body s cells and be used for energy. Insulin lowers blood sugar.
More informationDiabetes: What You Need to Know
UW MEDICINE PATIENT EDUCATION Diabetes: What You Need to Know Discharge review before you leave the hospital We want to be sure that we explained your diabetes instructions well, so that you know how to
More informationAdvanced Pharmacology Diabetes Homework
Advanced Pharmacology Diabetes Homework Points: 25 Comments: Name: Tracy Hill WU ID #: 20015608 E-mail: tracy.hill@washburn.edu _TH I hereby certify that the work submitted is my own, and that I have not
More informationUsing Insulin in the Primary Care Setting: Interactive Cases
Using Insulin in the Primary Care Setting: Interactive Cases Irl B. Hirsch, MD University of Washington School of Medicine Dualities (Nov, 2011) Research Grants: sanofi-aventis, Novo Nordisk, Halozyme,
More informationWhat do you need to know before you go home?
What do you need to know before you go home? What is Insulin Types of Insulin Injection Sites How to Inject Insulin Correctly Low Blood Sugar and Treatment Sick Day Management After leaving the Hospital:
More informationThe York Diabetes Care Model
This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin
More informationPrior to making any insulin adjustments the following knowledge and skills are required:
Diabetes Control Diabetes Control Food, activity and insulin influence your blood glucose levels. At times it may seem like a juggling act as you attempt to balance these three factors. Home blood glucose
More informationANGELA GINN-MEADOW RD LDN CDE
DIABETES DRUGS & TRENDS MADE SIMPLE PHARMD TO RD ANGELA GINN-MEADOW RD LDN CDE OBJECTIVES At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationDate of Birth. Black/African American. What is your occupation? Retired? Yes No
Health Risk Assessment Today s Date: Name Date of Birth GENERAL INFORMATION What is your race? American Indian or Alaskan Native Native Hawaiian or Other Pacific Islander Asian, Chinese, Japanese, Korean
More informationTEAMcare Treat-to-Target Tools
TEAMcare Treat-to-Target Tools The TEAMcare Treatment Discussion Tool (treatment protocol) Nurse Case Manager (NCM)-MD Treat-to-Target Discussion Tool for Treatment Enhancement Activation and Motivation
More informationManagement: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018
Management: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018 Disclosures I have no Objectives Use a case-based format to discuss diabetes management pearls Discuss
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationInsulin Intensification: A Patient-Centered Approach
MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director
More informationPHYSICIANS INTERACTIVE PARTICIPANT GUIDE
PHYSICIANS INTERACTIVE PARTICIPANT GUIDE Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationDiabetes Mellitus Type 2
Diabetes Mellitus Type 2 What is it? Diabetes is a common health problem in the U.S. and the world. In diabetes, the body does not use the food it digests well. It is hard for the body to use carbohydrates
More informationRISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES
RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES Risk Factors or Complications Glycemic Control Fasting & Capillary Plasma Glucose Anti-platelet
More informationDiabetes Family Medicine Board Review
Diabetes Family Medicine Board Review Sarah Kim, MD Assistant Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March 10, 2016 No disclosures Diabetes Test Topics Majority Type
More informationDiabetes Family Medicine Board Review
Diabetes Family Medicine Board Review Sarah Kim, MD Associate Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March 21, 2018 No disclosures Diabetes Test Topics Majority Type
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationImproving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies
Improving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies Leigh Briscoe-Dwyer, PharmD, BCPS, FASHP Chief Pharmacy and Medication Safety Officer North Shore Long Island Jewish Health
More informationTreat-to-Target Tools
TEAMcare Care Manager Primary Care Provider Treat to Target Discussion Tool for Treatment Enhancement Activation and Motivation (TEAM) Depression, Diabetes and Coronary Heart Disease (CHD) Intervention
More informationInsulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination. Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM
Insulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM University of Mississippi School of Pharmacy Joshua J. Neumiller, Pharm.D., CDE, FAADE,
More informationTopic: Chronic Heart Failure Cases for Monday s March 21th lecture.
1 Phar6122: CV section Date: 3/10/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In
More informationJournal Club September 29, Vanessa AKIKI PGYlII Internal Medicine
Journal Club September 29, 2017 Vanessa AKIKI PGYlII Internal Medicine AUBMC 2017 Case Presentation 41-year-old man who was diagnosed with type 1 diabetes 21 years ago presents to your clinic. He believes
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationPoll Question 2. Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services.
Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Poll Question 1 Mary takes 6 units lispro (Humalog) before dinner. Which BG result reflects
More informationLearning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications
Treatment Strategies to Maximize the Value of Diabetes Medications Presenters: Jennifer Toy, PharmD, BCACP and Crystal Zhou, PharmD, APh AHSCP, BCACP Learning Objectives 1. Discuss which patients may benefit
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More information!"#$%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!(((
!"#%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!((( 26%5&"7%'( At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for weight loss Understand
More informationInsulin Basic facts. Patient Education Patient Care Services. What is insulin? What types of insulin are there? Basal Insulin
Patient Education Insulin Basic facts Insulin is a protein made by the pancreas that allows your cells to use glucose for energy. There are different types of insulin: Basal long-acting insulin that controls
More informationExternal Examiner: Miss C Biggs Internal Examiner: Mrs S Ogilvie DURATION: 3 HOURS TOTAL MARKS: 150
External Examiner: Miss C Biggs Internal Examiner: Mrs S Ogilvie DURATION: 3 HOURS TOTAL MARKS: 150 NOTE THIS PAPER CONSISTS OF SEVEN (7) PAGES AND APPENDIX A ONE (1) PAGE AND APPENDIX B ONE (1) PAGE PLEASE
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationPhysiology of Normoglycemia
Case 1 45 year-old male patient seen at the clinic (Medicine). Workplace stress (financial analyst); occasionally goes jogging. Two-year duration of T2DM. No previous cardiovascular events. Coexisting
More information2/4/13. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing
Step 1: Determine etween Intensive Insulin Therapy or Conventional Insulin Therapy Intensive Insulin Therapy (IIT) y definition, IIT attempts to mimic the body s normal release of insulin and therefore,
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More information4/2/2018. Human U-500 insulin Learning Objectives. Dr. Ken Cathcart FACE
Human U-500 insulin 2018 Dr. Ken Cathcart FACE Learning Objectives Participants will be able to identify when it is appropriate to use U500 insulin Participants will be able to state how to determine a
More informationPremixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s
Premixed Insulin for Type 2 Diabetes a gu i d e f o r a d u lt s March 2009 What This Guide Covers / 2 Type 2 Diabetes / 3 Learning About Blood Sugar / 4 Learning About Insulin / 5 Comparing Medicines
More informationDIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address:
1 DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address: 2 Learning Outcomes All nurses, regardless of practice setting, are required to work collaboratively with the person
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationClinical Insights Into a New, Disposable Insulin Delivery Device
care innovations Clinical Insights Into a New, Disposable Insulin Delivery Device P. Gaye Knutsen, 1 Cheryl Q. Voelker, 1 and Carla C. Nikkel 2 1 Washington University Diabetes Center at Barnes Jewish
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationInnovative, Unusual Therapies for DM-2: Insulin U-500, Bromocriptine, Colesevelam, and SGLT2 inhibitors. April 3 rd, 2014
Innovative, Unusual Therapies for DM-2: Insulin U-500, Bromocriptine, Colesevelam, and SGLT2 inhibitors April 3 rd, 2014 KM Pantalone Associate Staff Endocrinology Speaker Bureau: Disclosures Bristol-Myers
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information